EGFR, p16, HPV titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer

Journal of Clinical Oncology

Volumn 26, Issue 19, 2008, Pages 3128-3137

  Kumar, Bhavna ^a   Cordell, Kitrina G ^a   Lee, Julia S ^a   Worden, Francis P ^a   Prince, Mark E ^a   Tran, Huong H ^a   Wolf, Gregory T ^a   Urba, Susan G ^a   Chepeha, Douglas B ^a   Teknos, Theodoros N ^a   Eisbruch, Avraham ^a   Tsien, Christina I ^a   Taylor, Jeremy M G ^a   D'Silva, Nisha J ^a   Yang, Kun ^a   Kurnit, David M ^a   Bauer, Joshua A ^a   Bradford, Carol R ^a   Carey, Thomas E ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; PACLITAXEL; PROTEIN BCL XL; PROTEIN P16; PROTEIN P53; CYCLIN DEPENDENT KINASE INHIBITOR 2A; PROTEIN BCL X; TUMOR MARKER; VIRUS DNA;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BIOPSY TECHNIQUE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CANCER THERAPY; CLINICAL TRIAL; FEMALE; GENE MUTATION; HISTORY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; ORGAN; OROPHARYNX CANCER; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; SEX; SMOKING; SMOKING CESSATION; STATISTICAL SIGNIFICANCE; TREATMENT RESPONSE; VIRUS MUTANT; WART VIRUS; WILD TYPE; BIOPSY; ENZYME IMMUNOASSAY; GENETICS; ISOLATION AND PURIFICATION; METABOLISM; MIDDLE AGED; NONPARAMETRIC TEST; NUCLEOTIDE SEQUENCE; OROPHARYNX TUMOR; PAPILLOMA VIRUS; SEX DIFFERENCE; SURVIVAL; TREATMENT OUTCOME;

AGED; BCL-X PROTEIN; BIOPSY; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA MUTATIONAL ANALYSIS; DNA, VIRAL; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; OROPHARYNGEAL NEOPLASMS; PAPILLOMAVIRIDAE; PROSPECTIVE STUDIES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SEX FACTORS; SMOKING; STATISTICS, NONPARAMETRIC; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 49249095295     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.12.7662     Document Type: Article

References (58)

1. Worden FP, Kumar B, Lee JS, et al: Chemoselection as a strategy for organ preservation in advanced oropharynx cancer: Response and survival positively associated with HPV16 copy number. J Clin Oncol 26:3138-3146, 2008
2. Gillison ML, Koch WM, Capone RB, et al: Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 92:709-720, 2000
3. Li G & Sturgis EM: The role of human papillomavirus in squamous carcinoma of the head and neck. Curr Oncol Rep 8:130-139, 2006
4. Fakhry C & Gillison ML: Clinical implications of human papillomavirus in head and neck cancers. J Clin Oncol 24:2606-2611, 2006
5. Ringstrom E, Peters E, Hasegawa M, et al: Human papillomavirus type 16 and squamous cell carcinoma of the head and neck. Clin Cancer Res 8:3187-3192, 2002
6. Tran N, Rose BR & O'Brien C J: Role of human papillomavirus in the etiology of head and neck cancer. Head Neck 29:64-70, 2007
7. Li W, Thompson CH, Cossart YE, et al: The expression of key cell cycle markers and presence of human papillomavirus in squamous cell carcinoma of the tonsil. Head Neck 26:1-9, 2004
8. Strome SE, Savva A, Brissett AE, et al: Squamous cell carcinoma of the tonsils: A molecular analysis of HPV associations. Clin Cancer Res 8:1093-1100, 2002
9. Licitra L, Perrone F, Bossi P, et al: High-risk human papillomavirus affects prognosis in patients with surgically treated oropharyngeal squamous cell carcinoma. J Clin Oncol 24:5630-5636, 2006
10. Mellin H, Friesland S, Lewensohn R, Dalianis T, Munck-Wikland E: Human papillomavirus (HPV) DNA in tonsillar cancer: Clinical correlates, risk of relapse, and survival. Int J Cancer 89:300-304, 2000
11. Lindel K, Beer KT, Laissue J, Greiner RH, Aebersold DM: Human papillomavirus positive squamous cell carcinoma of the oropharynx: A radiosensitive subgroup of head and neck carcinoma. Cancer 92:805-813, 2001
12. Obiso R, Lorincz A: Digene Corporation. Pharmacogenomics 5:129-132, 2004
13. Yang H, Yang K, Khafagi A, et al: Sensitive detection of human papillomavirus in cervical, head/ neck, and schistosomiasis-associated bladder malignancies. Proc Natl Acad Sci U S A 102:7683-7688, 2005
14. Zhang HS, Postigo AA, Dean DC: Active transcriptional repression by the Rb-E2F complex mediates G1 arrest triggered by p16INK4a, TGFbeta, and contact inhibition. Cell 97:53-61, 1999
15. Worsham MJ, Chen KM, Tiwari N, et al: Fine-mapping loss of gene architecture at the CDKN2B (p15INK4b), CDKN2A (p14ARF, p16INK4a), and MTAP genes in head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 132:409-415, 2006
16. Yarbrough WG: The ARF-p16 gene locus in carcinogenesis and therapy of head and neck squamous cell carcinoma. Laryngoscope 112:2114-2128, 2002
17. Begum S, Gillison ML, Ansari-Lari MA, et al: Detection of human papillomavirus in cervical lymph nodes: A highly effective strategy for localizing site of tumor origin. Clin Cancer Res 9:6469-6475, 2003
18. Dehn D, Torkko KC, Shroyer KR: Human papillomavirus testing and molecular markers of cervical dysplasia and carcinoma. Cancer 111:1-14, 2007
19. Klussmann JP, Gultekin E, Weissenborn SJ, et al: Expression of p16 protein identifies a distinct entity of tonsillar carcinomas associated with human papillomavirus. Am J Pathol 162:747-753, 2003
20. Hynes NE, Lane HA: ERBB receptors and cancer: The complexity of targeted inhibitors. Nat Rev Cancer 5:341-354, 2005
21. Ettinger DS: Clinical implications of EGFR expression in the development and progression of solid tumors: Focus on non-small cell lung cancer. Oncologist 11:358-373, 2006
22. Kalyankrishna S, Grandis JR: Epidermal growth factor receptor biology in head and neck cancer. J Clin Oncol 24:2666-2672, 2006
23. Pivot X, Magne N, Guardiola E, et al: Prognostic impact of the epidermal growth factor receptor levels for patients with larynx and hypopharynx cancer. Oral Oncol 41:320-327, 2005
24. Santini J, Formento JL, Francoual M, et al: Characterization, quantification, and potential clinical value of the epidermal growth factor receptor in head and neck squamous cell carcinomas. Head Neck 13:132-139, 1991
25. Psyrri A, Yu Z, Weinberger PM, et al: Quantitative determination of nuclear and cytoplasmic epidermal growth factor receptor expression in oropharyngeal squamous cell cancer by using automated quantitative analysis. Clin Cancer Res 11:5856-5862, 2005
26. Aebersold DM, Froehlich SC, Jonczy M, et al: Expression of transforming growth factor-alpha, epidermal growth factor receptor and platelet-derived growth factors A and B in oropharyngeal cancers treated by curative radiation therapy. Radiother Oncol 63:275-283, 2002
27. Smith BD, Smith GL, Carter D, et al: Molecular marker expression in oral and oropharyngeal squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 127:780-785, 2001
28. Ahomadegbe JC, Barrois M, Fogel S, et al: High incidence of p53 alterations (mutation, deletion, overexpression) in head and neck primary tumors and metastases; absence of correlation with clinical outcome. Frequent protein overexpression in normal epithelium and in early non-invasive lesions. Oncogene 10:1217-1227, 1995
29. Bradford CR, Zhu S, Poore J, et al: p53 mutation as a prognostic marker in advanced laryngeal carcinoma: Department of Veterans Affairs Laryngeal Cancer Cooperative Study Group. Arch Otolaryngol Head Neck Surg 123:605-609, 1997
30. Nogueira CP, Dolan RW, Gooey J, et al: Inactivation of p53 and amplification of cyclin D1 correlate with clinical outcome in head and neck cancer. Laryngoscope 108:345-350, 1998
31. Carlos de Vicente J, Junquera Gutierrez LM, Zapatero AH, et al: Prognostic significance of p53 expression in oral squamous cell carcinoma without neck node metastases. Head Neck 26:22-30, 2004
32. Khademi B, Shirazi FM, Vasei M, et al: The expression of p53, c-erbB-1 and c-erbB-2 molecules and their correlation with prognostic markers in patients with head and neck tumors. Cancer Lett 184:223-230, 2002
33. Erber R, Conradt C, Homann N, et al: TP53 DNA contact mutations are selectively associated with allelic loss and have a strong clinical impact in head and neck cancer. Oncogene 16:1671-1679, 1998
34. Mineta H, Borg A, Dictor M, et al: p53 mutation, but not p53 overexpression, correlates with survival in head and neck squamous cell carcinoma. Br J Cancer 78:1084-1090, 1998
35. Bosch FX, Ritter D, Enders C, et al: Head and neck tumor sites differ in prevalence and spectrum of p53 alterations but these have limited prognostic value. Int J Cancer 111:530-538, 2004
36. Gapany M, Pavelic ZP, Gapany SR, et al: Relationship between immunohistochemically detectable p53 protein and prognostic factors in head and neck tumors. Cancer Detect Prev 17:379-386, 1993
37. Pukkila MJ, Kumpulainen EJ, Virtaniemi JA, et al: Nuclear and cytoplasmic p53 expression in pharyngeal squamous cell carcinoma: Prognostic implications. Head Neck 24:784-791, 2002
38. Vlachtsis K, Nikolaou A, Markou K, et al: Clinical and molecular prognostic factors in operable laryngeal cancer. Eur Arch Otorhinolaryngol 262:890-898, 2005
39. Adams JM, Cory S: The Bcl-2 protein family: Arbiters of cell survival. Science 281:1322-1326, 1998
40. Reed JC, Miyashita T, Takayama S, et al: BCL-2 family proteins: Regulators of cell death involved in the pathogenesis of cancer and resistance to therapy. J Cell Biochem 60:23-32, 1996
41. Bauer JA, Trask DK, Kumar B, et al: Reversal of cisplatin resistance with a BH3 mimetic, (-)-gossypol, in head and neck cancer cells: Role of wild-type p53 and Bcl-xL. Mol Cancer Ther 4:1096-1104, 2005
42. Urba S, Wolf G, Eisbruch A, et al: Single-cycle induction chemotherapy selects patients with advanced laryngeal cancer for combined chemoradiation: A new treatment paradigm. J Clin Oncol 24:593-598, 2006
43. Worden FP, Urba S, Bradford C, et al: One cycle of induction chemotherapy (IC) in advanced oropharyngeal cancer (SCOOP) to select patients for organ preservation (OP). J Clin Oncol 23:16s, 2005 (suppl; abstr 5512)
44. Prince ME, Ubell ML, Castro J, et al: Tissue-preserving approach to extracting DNA from paraffin-embedded specimens using tissue microarray technology. Head Neck 29:465-471, 2007
45. Kim SH, Koo BS, Kang S, et al: HPV integration begins in the tonsillar crypt and leads to the alteration of p16, EGFR and c-myc during tumor formation. Int J Cancer 120:1418-1425, 2007
46. Reimers N, Kasper HU, Weissenborn SJ, et al: Combined analysis of HPV-DNA, p16 and EGFR expression to predict prognosis in oropharyngeal cancer. Int J Cancer 120:1731-1738, 2007
47. Almadori G, Cadoni G, Cattani P, et al: Human papillomavirus infection and epidermal growth factor receptor expression in primary laryngeal squamous cell carcinoma. Clin Cancer Res 7:3988-3993, 2001
48. Johnston D, Hall H, DiLorenzo TP, et al: Elevation of the epidermal growth factor receptor and dependent signaling in human papillomavirus-infected laryngeal papillomas. Cancer Res 59:968-974, 1999
49. Hafkamp HC, Manni JJ, Speel EJ: Role of human papillomavirus in the development of head and neck squamous cell carcinomas. Acta Otolaryngol 124:520-526, 2004
50. Klussmann JP, Weissenborn SJ, Wieland U, et al: Prevalence, distribution, and viral load of human papillomavirus 16 DNA in tonsillar carcinomas. Cancer 92:2875-2884, 2001
51. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer: The Department of Veterans Affairs Laryngeal Cancer Study Group. N Engl J Med 324:1685-1690, 1991
52. Kumar B, Cordell KG, D'Silva N, et al: Expression of p53 and Bcl-xL as predictive markers for larynx preservation in advanced laryngeal cancer. Arch Otolaryngol Head Neck Surg 134:363-369, 2008
53. Bradford CR, Zhu S, Ogawa H, et al: p53 mutation correlates with cisplatin sensitivity in head and neck squamous cell carcinoma lines. Head Neck 25:654-661, 2003
54. Hafkamp HC, Speel EJ, Haesevoets A, et al: A subset of head and neck squamous cell carcinomas exhibits integration of HPV 16/18 DNA and overexpression of p16INK4A and p53 in the absence of mutations in p53 exons 5-8. Int J Cancer 107:394-400, 2003
55. Lingen MW, Chang KW, McMurray SJ, et al: Overexpression of p53 in squamous cell carcinoma of the tongue in young patients with no known risk factors is not associated with mutations in exons 5-9. Head Neck 22:328-335, 2000
56. Oliver CL, Bauer JA, Wolter KG, et al: In vitro effects of the BH3 mimetic, (-)-gossypol, on head and neck squamous cell carcinoma cells. Clin Cancer Res 10:7757-7763, 2004
57. Verhaegen M, Bauer JA, Martin de la Vega C, et al: A novel BH3 mimetic reveals a mitogen-activated protein kinase-dependent mechanism of melanoma cell death controlled by p53 and reactive oxygen species. Cancer Res 66:11348-11359, 2006
58. Oltersdorf T, Elmore SW, Shoemaker AR, et al: An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435:677-681, 2005